Loading...
OTCMENDV
Market cap127kUSD
Dec 24, Last price  
0.00USD
1D
-11.11%
1Q
-69.23%
Jan 2017
-100.00%
IPO
-100.00%
Name

Endonovo Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:ENDV chart
P/E
0.02
P/S
0.91
EPS
0.02
Div Yield, %
0.00%
Shrs. gr., 5y
417.92%
Rev. gr., 5y
10.99%
Revenues
140k
+3.61%
60,00060,58547,76730,58122,89624,1924,2650083,263310,164165,79673,105135,355140,242
Net income
7m
P
-330,000-69,400-94,088-1,914,551-2,892,794-959,494-5,079,101-5,315,672-10,810,160-6,435,839-23,404,749-2,026,563-4,046,460-32,138,4876,924,594
CFO
122k
P
-80,0008,502-50,354-284,891-257,416-909,296-1,019,334-2,462,334-2,989,770-2,878,834-2,541,007-741,590-986,584-678,838121,870

Profile

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
URL
https://endonovo.com/
IPO date
Mar 09, 2012
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
140
3.61%
135
85.15%
73
-55.91%
Cost of revenue
655
10
15
Unusual Expense (Income)
NOPBT
(515)
125
58
NOPBT Margin
92.62%
79.50%
Operating Taxes
13,664
942
Tax Rate
10,899.10%
1,620.04%
NOPAT
(515)
(13,538)
(883)
Net income
6,925
-121.55%
(32,138)
694.24%
(4,046)
99.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
11
142
126
BB yield
-0.09%
-5.67%
-13.50%
Debt
Debt current
7,073
7,153
7,181
Long-term debt
80
80
Deferred revenue
Other long-term liabilities
80
Net debt
7,069
7,231
7,173
Cash flow
Cash from operating activities
122
(679)
(987)
CAPEX
Cash from investing activities
Cash from financing activities
(120)
593
1,059
FCF
(9,153)
2,249
(602)
Balance
Cash
2
98
86
Long term investments
2
2
2
Excess cash
84
Stockholders' equity
(68,234)
(75,098)
(56,436)
Invested Capital
51,280
50,151
47,923
ROIC
ROCE
3.03%
EV
Common stock shares outstanding
1,350,768
139,207
59,837
Price
0.01
-51.67%
0.02
15.38%
0.02
-22.39%
Market cap
11,752
368.99%
2,506
168.44%
933
280.16%
EV
18,821
9,737
8,107
EBITDA
132
772
707
EV/EBITDA
142.15
12.61
11.47
Interest
1,282
1,322
942
Interest/NOPBT
1,054.18%
1,620.04%